HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia

Table 3 Association between effective treatment and HLAB27 allele type

Treatment Groups	SS+ MTX n = 7, OR/χ²/p	MTX n = 24, OR/χ²/p	SS n = 18, OR/χ²/p	MTX+ Enbrel n = 7, OR/χ²/p	All children with JIA n = 56 , gf
HLA B*27 subtypes
*2702	-	0.57/0.13/0.01**	2.26/1.75/0.65	-	0.07
*2703	-	0.08	-	2.94/0.50/0.02	0.05
*2704	-	-	3.24/0.38/0.22	-	0.02
*2705	2.02/0.16/0.05	1.13/0.54/0.03	0.05	0.6/0.35/0.02**	0.55
*2710	0.29	0.08	0.49/0.35/0.05**	0.14	0.11
*2715	-	0.04	3.24/0.38/0.22	-	0.04
*2717	-	0.08	0.06	0.14	0.07
*2728	-	0.08	0.11	0.14	0.10

* HLA B*27 subtypes
JIA - children with juvenile idiopathic arthritis
** type protective statistically significant association for patients all JIA subjects
Results are only shown for those alleles where there was evidence for a difference between JIA subgroups.
Group SS +MTX indicates combination therapy with Sulfasalazine and Methotrexate
Group MTX indicates therapy with Methotrexate;
Group MTX+Enbrel indicate combination therapy with Methotrexate and Enbrel;
Bold-face type highlights statistically significant associations for patients all JIA subjects;
gf (allele frequency), P (probability), OR (odds ratio) and x² values of OR are reported only for significant associations ( P < 0.05)
n = number of patients

ISSN: 1546-0096